Atlas Trials

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

Clinical trial NCT04158856 · NOT_YET_RECRUITING

Trial details

NCT number
NCT04158856
Sponsor
xuexin he
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2020-06-01
Primary completion
2023-05-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.